Literature DB >> 15665861

TNF alpha reduces tachykinin, PGE2-dependent, relaxation of the cultured mouse trachea by increasing the activity of COX-2.

Ofir Bachar1, Andrew C Rose, Mikael Adner, Xudong Wang, Clodagh E Prendergast, Ashley Kempf, Nigel P Shankley, Lars-Olaf Cardell.   

Abstract

1. Chronic inflammation is a central feature of asthma. The inflammatory cytokine tumour necrosis factor alpha (TNFalpha) has been implicated in this disease, and is known to alter airway smooth muscle functionally. 2. The aim of this study was to investigate the influence of TNFalpha on tachykinin-induced airway relaxation. Mouse tracheae were cultured in the absence and presence of TNFalpha for 1 or 4 days. 3. In the absence of TNFalpha, substance P (SP) and neurokinin A (NKA) induced comparable levels of relaxation in fresh and cultured segments. Functional studies with selective antagonists/inhibitors indicated that the relaxation was mediated by the NK(1) receptor coupled to cyclooxygenase (COX)-2 activation and subsequent release of prostaglandin E(2) (PGE(2)). TNFalpha attenuated SP- and NKA-induced relaxation in a time- and concentration-dependent manner, decreasing the ability of PGE(2) to relax tissues. 4. Further studies indicated that TNFalpha elevated COX-2 activity and that concomitant inhibition of COX-2 reversed TNFalpha-attenuated PGE(2) relaxation. Culture with PGE(2) decreased SP- and PGE(2)-mediated relaxation, further implicating the activity of COX-2 in the attenuation of tachykinin signalling. 5. Gene expression analysis demonstrated that TNFalpha increased the expression of smooth muscle COX-2, PGE(2) synthase and EP(2) receptor mRNA, and decreased the expression of the EP(4) receptor. 6. Overall, these results show that NK(1) receptor-mediated relaxation induced by PGE(2) is attenuated by prolonged TNFalpha stimulation. Increased COX-2 activity induced by TNFalpha appears to be central to this process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15665861      PMCID: PMC1575996          DOI: 10.1038/sj.bjp.0706067

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor.

Authors:  X Emonds-Alt; P Vilain; P Goulaouic; V Proietto; D Van Broeck; C Advenier; E Naline; G Neliat; G Le Fur; J C Brelière
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

2.  Amplified RNA synthesized from limited quantities of heterogeneous cDNA.

Authors:  R N Van Gelder; M E von Zastrow; A Yool; W C Dement; J D Barchas; J H Eberwine
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

3.  Modulatory role of tachykinin NK1 receptor in cholinergic contraction of mouse trachea.

Authors:  K G Tournoy; K O De Swert; P G Leclere; R A Lefebvre; R A Pauwels; G F Joos
Journal:  Eur Respir J       Date:  2003-01       Impact factor: 16.671

4.  Optimisation of real-time quantitative RT-PCR for the evaluation of non-viral mediated gene transfer to the airways.

Authors:  A C Rose; C A Goddard; W H Colledge; S H Cheng; D R Gill; S C Hyde
Journal:  Gene Ther       Date:  2002-10       Impact factor: 5.250

Review 5.  New insights into the relationship between airway inflammation and asthma.

Authors:  A J Wardlaw; C E Brightling; R Green; G Woltmann; P Bradding; I D Pavord
Journal:  Clin Sci (Lond)       Date:  2002-08       Impact factor: 6.124

6.  Human cyclooxygenase-2 cDNA.

Authors:  T Hla; K Neilson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

7.  Relationship between the tumor necrosis factor system and the serum interleukin-4, interleukin-5, interleukin-8, eosinophil cationic protein, and immunoglobulin E levels in the bronchial hyperreactivity of adults and their children.

Authors:  A Halász; E Cserháti; L Kósa; K Cseh
Journal:  Allergy Asthma Proc       Date:  2003 Mar-Apr       Impact factor: 2.587

8.  Cytokines in symptomatic asthma airways.

Authors:  D H Broide; M Lotz; A J Cuomo; D A Coburn; E C Federman; S I Wasserman
Journal:  J Allergy Clin Immunol       Date:  1992-05       Impact factor: 10.793

9.  Effect of inhaled prostaglandin E2 on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma.

Authors:  I D Pavord; A Wisniewski; R Mathur; I Wahedna; A J Knox; A E Tattersfield
Journal:  Thorax       Date:  1991-09       Impact factor: 9.139

10.  Tumor necrosis factor causes bronchial hyperresponsiveness in rats.

Authors:  J C Kips; J Tavernier; R A Pauwels
Journal:  Am Rev Respir Dis       Date:  1992-02
View more
  4 in total

1.  TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells.

Authors:  Stuart S Hobbs; Jeremy A Goettel; Dongchun Liang; Fang Yan; Karen L Edelblum; Mark R Frey; Matthew T Mullane; D Brent Polk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-05-12       Impact factor: 4.052

2.  Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets.

Authors:  Matthew B Greenblatt; Jennifer L Sargent; Giuseppina Farina; Kelly Tsang; Robert Lafyatis; Laurie H Glimcher; Michael L Whitfield; Antonios O Aliprantis
Journal:  Am J Pathol       Date:  2012-01-11       Impact factor: 4.307

3.  Essential role of IFNbeta and CD38 in TNFalpha-induced airway smooth muscle hyper-responsiveness.

Authors:  Deepika Jain; Stefan Keslacy; Omar Tliba; Yang Cao; Sonja Kierstein; Kunjlata Amin; Reynold A Panettieri; Angela Haczku; Yassine Amrani
Journal:  Immunobiology       Date:  2008-01-29       Impact factor: 3.144

4.  Enhancement of methacholine-evoked tracheal contraction induced by bacterial lipopolysaccharides depends on epithelium and tumor necrosis factor.

Authors:  T Secher; F Rodrigues Coelho; N Noulin; A Lino Dos Santos Franco; V Quesniaux; J Lignon; J Mitchell; R Moser; E Gomes; L Mirotti; W Tavares-de-Lima; B Ryffel; B Boris Vargaftig; M Russo
Journal:  J Allergy (Cairo)       Date:  2012-03-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.